martes, 6 de octubre de 2026
BuscarExplore
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Press releaseGlobeNewswire· June 12, 2026

The New Bottleneck Isn’t Computing Power — It’s Just Power

View original at globenewswire.com
The New Bottleneck Isn’t Computing Power — It’s Just Power Issued on behalf of LIXTE Biotechnology Holdings, Inc. America can build data centers in months, but the electricity to run them can take half a decade to arrive…
Opening lines of the source · GlobeNewswire · short snapshot — read the full document at the original

Lo que extrajimos de esta fuente

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • NOMAD's manufacturing roadmap scales from approximately 2.5 gigawatts of production capacity in 2026 to approximately 3.5 gigawatts in 2027.

    60% confidence
  • NOMAD achieved revenue growth of approximately 175% year-over-year in 2025 (management figures, not audited results).

    60% confidence
  • Inbound opportunities represent approximately 75% of NOMAD's sales activity.

    60% confidence
  • NOMAD's mobile transportable platform avoids land-use entitlements and zoning variances, reduces or eliminates NEPA/CEQA environmental review, skips the multi-year interconnection queue, and can operate in jurisdictions where permanent batteries are banned outright.

    60% confidence
  • NOMAD projects revenue growth of roughly 135% in 2026 (management projection, not a guarantee).

    60% confidence
  • NOMAD projects revenue growth in excess of 285% in 2027 (management projection, not a guarantee).

    60% confidence
  • NOMAD is tracking more than 30 active utility, infrastructure, and strategic customer opportunities across North America.

    60% confidence
  • NOMAD's total addressable market comprises roughly 3,200 electric utilities plus thousands of industrial users and a fast-growing base of AI infrastructure operators.

    60% confidence
  • Permanent, grid-scale battery storage projects in North America routinely face development timelines of two to five years or longer due to multi-agency permitting including NEPA, CEQA, land-use entitlements, zoning variances, fire review, and interconnection queues.

    60% confidence
  • Summer peak electricity demand across North America will climb by 224 gigawatts over the next decade, and several major grid regions face elevated risk of supply shortfalls.

    60% confidence
  • Approximately 2.3 terawatts of generation and storage capacity are currently sitting in U.S. interconnection queues, while development timelines have stretched from about two years historically to five to seven years or longer.

    60% confidence
  • Access to power is becoming one of the defining economic challenges of the next decade.

    60% confidence
  • In New York State alone, 108 local jurisdictions have enacted moratoria or bans on permanent battery storage development, with roughly a gigawatt of storage sidelined under such restrictions.

    60% confidence
  • This transaction creates one of the first publicly traded companies singularly focused on solving one of the most significant constraints facing economic growth today — access to reliable electrical power.

    60% confidence
  • NOMAD is the market leader in deployable, utility-grade battery energy storage and the first to bring a mobile, utility-grade 1 MW battery system to market.

    60% confidence

Citado en estos reportajes de Via News

Lo que sabemos · la inteligencia detrás de esta página
En vivo desde el sustrato
Lo que estamos viendo
Obesity and Immunology Readouts, Big Pharma M&A and AI-Designed Drugs Converge Into a Q4 2026 Catalyst Wave
Late-stage data and deal activity are clustering ahead of Q4 2026. Novo Nordisk's CagriSema won Best Abstract at EASD 2026 for its brain and body (fMRI/MRI) data, Lilly showed ADtouch results for EBGLYSS and agreed to buy Merida Biosciences for $2.9B, and Merck's tulisokibart hit its Phase 2b endpoints. A key regulatory catalyst follows: the FDA PDUFA date for the ivonescimab BLA on 2026-11-14. AI-designed rentosertib showing anti-aging effects adds a speculative AI-drug-discovery thread, while QAIAx's microcities trial and QIII pilot (planned 2027-01-01) are peripheral, forecast-only items.
Nuestra lectura de los datos ›
Señales que seguimos
Satellite-Terrestrial Network Integration Acceleration
Increased investment and launches in hybrid satellite-cellular networks across telecom industry; competitive responses from other carriers; regulatory activity around satellite spectrum; expansion of emergency/rural connectivity use cases
Patrones que observamos ›
Donde las fuentes discrepan
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
Señalamos los conflictos abiertamente ›
Verificado recientemente
✓ Verificado con la fuente original
4,985
hechos rastreados a su fuente — y señalamos los que no se sostienen.
101 entidades seguidas4,985 hechos verificados con la fuente5,351 documentos fuente archivados
Consulta estos datos → isubstrate.com